Currently, clinical trials are ongoing to evaluate the efficacy of PD-1/PD-L1 inhibitors as monotherapy or part of combined therapeutic strategies in HCC patients (Table 1). The gene discussed is PDCD1; the disease is hepatocellular carcinoma.